




WHO warned that Substandard and Falsified medical products (SFs) can harm patients and fail to 
treat the diseases for which they were intended and they lead to loss of confidence in medicines, 
healthcare providers and health systems, and affect every region of the world. Development of 
analytical procedure for detecting SFs is the key to grasp the distribution of the SFs and to 
understand the physical and chemical properties of the SFs to take measure to suppress the public 
health damage. There are various analytical methods defined for the analysis of a specific medical 
product, such as published in the pharmacopeias, but the discrimination methods to investigate the 
authenticity for detecting SFs which are actually distributed on the global market are still limited. 
Further, there are also few studies on how to apply the analytical technologies to discriminate the 
SFs with the portable device for in-situ measurements, non-destructive methods for evidence 
preservation of SFs, easy to use and low cost for easy introduction of those technologies, speedy 
measurements in order to grasp the actual situation immediately and to suppress damage to public 
health. This paper is composed of three chapters.  
 
Chapter I delivers how to visualize the physical and chemical properties of falsified medical 
products with the combination technology of Handheld Raman Spectroscopy and X-ray Computed 
Tomography. Research to understand how the physical and chemical properties of SFs can be most 
effectively applied to distinguish the SFs from authentic products has not yet been investigated 
enough. Here, we investigated the usefulness of two analytical methods, handheld Raman 
spectroscopy (handheld Raman) and X-ray computed tomography (X-ray CT), for detecting SFs 
among oral solid anti-hypertensive pharmaceutical products containing candesartan cilexetil as an 
active pharmaceutical ingredient (API). X-ray CT visualized at least two different types of falsified 
tablets as shown in Figure 1, one containing many cracks and voids and the other containing 
aggregates with high electron density, such as from the presence of the heavy elements.  
 




The Raman spectra of the API, lactose monohydrate (excipient) and the tablets are shown in Figure 2. 
The area surrounded by the dashed line covers the specific peak of API that does not overlap with the 
peaks of excipients. Other peaks are due to excipients, mainly from lactose monohydrate. The Raman 
spectra of each tablets including both API and lactose monohydrate are very similar. These results 
suggested that the handheld Raman technique can distinguish falsified products that are grossly 
different from authentic products, but cannot discriminate suspect samples with similar composition 
including an insufficient quantity of API. Generic products that purported to contain equivalent 
amounts of API to the authentic products were discriminated from the authentic products by the 
different physical structure on X-ray CT. 
 
Figure 2. The Raman spectra of the API, lactose monohydrate (excipient) and the tablets. 
 
Approach to investigate both the chemical and physical properties with handheld Raman and X-ray 
CT, respectively, promise the accurate discrimination of the SFs, even if their visual appearance is 
similar with authentic products. We present a decision tree (Figure 3) for investigating the 
authenticity of samples purporting to be authentic commercial tablets. Our results indicate that the 
combination approach of visual observation, handheld Raman and X-ray CT is a powerful strategy 






Figure 3.  Decision tree of combination approach for non-destructive discrimination 
between test samples and authentic product (8 mg). 
 
Chapter II shows the result of the survey to identify substandard and falsified tablets of 
hypertension medical products collected in China, Indonesia and Myanmar using the Japanese 
pharmacopeial analytical procedures for quality control, together with principal component analysis 
(PCA) of Raman spectra obtained with a handheld Raman spectrometer. The International 
Conference on Harmonisation (ICH) Q6A provides guidance to establish a harmonized set of global 
specifications consisting of analytical procedures and acceptance criteria for new drug substances 
(DS) and drug products (DP) for human use (1999). Specifications of DS and DP are proposed and 
justified by the manufacturer, and approved by regulatory authorities in each country. The 
specifications and acceptance criteria are focused on those chemical, physical and biological 
properties considered to be important for ensuring the safety and efficacy of DS and DP. Thus, they 
can be adopted to identify substandard products. Possible issues include 1) out-of-specification 
content of API, 2) significant dissolution delay, 3) contamination with toxic substances, and 4) lack 
of sterility. These points can be checked by means of assay, content uniformity testing, 
measurements of dissolution properties and impurities, and microbial tests. This research focused on 
methodology for detecting substandard and falsified medicines by PCA of raw data obtained by 
handheld Raman spectroscopy. It was aimed to clarify the chemical features of substandard 
medicines by comparing them with authentic medicines, and by extracting the principal components 
of the Raman spectrum to visualize the relationships among the tablets. We chose the handheld 
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Raman device as a simple spectroscope suitable for the speedy, easy to use, robust and in-situ 
observation in anywhere, and we employed PCA as a means to extract critical information despite 
the limited resolution and sensitivity of the device. We also compared signal preprocessing methods 
for PCA, and selected the multiplicative scattering correlation (MSC) method as being particularly 
suitable to extract the desired signals from the strong fluorescence background. The data interval of 
the hand-held device is around 1.4 to 2.2 cm-1, and the noise level is high, so preprocessing of the 
spectroscopy spectra is critical for accurate PCA calculation. It was used the Savitzky-Golay method 
to smooth each segment of the original Raman spectrum in a small window by fitting to a 
polynomial function. The MSC method was also applied to eliminate baseline shift caused by the 
multiplicative shift of the baseline tilts and the additive shift of the baseline shifts up and down. MSC 
can utilize data from many wavelengths to distinguish between light absorption and light scattering, 
correcting spectra according to a simple linear univariate fit to a standard spectrum by means of 
least-squares regression using the standard spectrum. The result of some samples showed delayed 
dissolution and failed to meet the Japanese pharmacopeial specification, while others failed the assay 
test. These products appeared to be substandard. PCA result showed that all Raman spectra could be 
explained in terms of two components: the concentration of the active pharmaceutical ingredient 
(API) and the kind of the excipient. These Raman spectra were conducted preprocessing and 
subjected to PCA in order to investigate the similarity of chemical components among samples. The 
calibration result and cross validation result in PCA model were compared and the result suggested 
that the difference among the samples can be clarified by using the two principal components of PC1 
and PC2 and the intensity change of Raman spectrum can be sufficiently expressed by PC1 and PC2. 
Therefore, the score plot was shown with the score of the PC1 and PC2 on the horizontal axis and the 
vertical axis, respectively for each tablet. Data set of the Raman spectra, which includes peaks from 
the API and main excipients, showed the intuitive interpretation score plot in the PCA result. Tablets 
collected in Myanmar were distributed around authentic Blopress tablets in the score plot, suggesting 
that similar excipients were used in both cases. On the other hand, the tablets collected in China 
showed a wide distribution on the score plot, suggesting that different excipients were used by 
different manufacturers. Notably, one manufacture’s tablets were placed very far from the other 
tablets, and there was a high positive correlation in PC2 and the falsified products collected in 
Indonesia were located similarly in the plot. In the loading of each PC in the calculated PCA model. 
The contribution rates were 84% of PC1, 7% of PC2 and 5% of PC3. PC2 was shown as a 
component extracted the characteristics of the signal derived from API, while PC1 showed the 
characteristics of the excipients of the lactose and others excipients.  The locations of samples 
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within the PCA score plot varied clearly according to the source country, suggesting that 
manufacturers in different countries employ different excipients as shown in Figure 4.  
 
Figure 4. PCA score plot derived from the Raman spectra of candesartan cilexetil 
tablets, including falsified tablets, collected in China and Myanmar. 
 
The results indicate that the handheld Raman device will be useful for detection of SFs and 
understand the correlation between the authenticities and other samples. PCA of that Raman data 
clarify the difference in chemical properties between good quality products and SFs that circulate in 
the Asian market. 
 
Chapter III is about the development and application of speedy and in-situ 3D fluorescence method 
for the injectable products. The falsified medicines for the injections have serious risks of the health 
hazards because the API is administrated directly into the blood, muscle and subcutaneous. It is 
conceivable that it is important to analyze quickly and to detect counterfeit drugs speedy at an early 
stage of the distribution. Since the injectable products that are not guaranteed the quality and that 
may have been prepared in poor environment lead to serious health damage, it is necessary to 
quickly detect the falsified products and to take measure. The falsified cases have been reported that 
imitated or stolen glass vial and packaging as same as those of the authentic products were used. 
Further, the injectable products are often clear liquids and it is difficult to visually identify the 
contents and to detect the falsified medicines easily. I investigated the analytical method for 
observing the contents in the glass vial from the outside of the glass vial without removing the 
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injectable solution from the glass vial. Especially, it was aimed to develop the speedy detection of 
the presence or absence of the active pharmaceutical ingredient (API). Further, both injections of 
Avastin and Herceptin targeted as the falsified medicines are molecular targeted therapeutic 
medicines and are compounds having the high molecular weight and the larger physical 
three-dimensional structure. Many APIs in the injectable solution include anticancer drugs with a 
relatively large molecular weight, and medicinal ingredients having large three-dimensional 
structures such as peptides, antibodies, and antibacterial drugs. These compounds usually have their 
own fluorescent properties. Therefore, the speedy and in-situ three-dimensional (3D) fluorescence 
method was developed to detect the API's fluorescence of various injections without removing the 
contents from the outside of the glass vial or preprocessing of the solution for the measurement. The 
sample was irradiated with excitation light of various wavelengths, and the emitted fluorescence 
intensity was measured every 5 nm. By plotting the excitation wavelength on the vertical axis, the 
fluorescence wavelength on the horizontal axis, and the fluorescence intensity in the height direction, 
it is possible to draw a three-dimensional contour diagram. A method for measuring such excited 
fluorescent three-dimensional matrix is called the EEMs (Excitation-Emission Matrices) method. To 
identify the API by EEMs method has high specificity based on the three-dimensional structure of 
the API in the injectable solution which was affected by the concentration of the API, buffer solution, 
excipients, pH, viscosity and temperature in the injection. The result of the EEMs showed the critical 
specificity of the characteristic fluorescent fingerprints derived from API itself were obtained in any 
of pharmaceuticals products such as peptides, small molecules and antibodies, and it was confirmed 
that they have high discriminating ability. And the new approach to measure was possible to measure 
the fluorescence from API in the parenteral products over the glass vial/ampoule without opening the 
lid of the glass vial/ampoule. This method is not limited by the size and shape of the glass container. 
This development of the cell unit was conducted in the joint with Hitachi. It was confirmed this 
method has phenomenal sensitivity compared with the method connecting an external optical fiber 
more than 100 times. For the injectable products including API which has fluorescence properties, 
the fluorescence EEMs measurement is very effective to discriminate the authenticity of the medical 
products. This research succeeded in measuring the specific fluorescence fingerprints of the API in 
the injectable products from the outside of the glassware material without affecting the shape and 
size of the glass with enough intensity of the fluorescence. In recent years, a non-destructive analysis 
method of the fluorescence by using the fiber probe has been developed. However, in this fiber probe 
method, the attenuate of the fluorescence intensity is observed due to the physical distance between 
the spectrometer and the measurement samples. Therefore, it was difficult to detect the EEMs with 
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the high sensitivity analysis in the conventional fiber probe method. In this study, by removing the 
conventional cell unit and measuring the samples of the injectable formulation, the detection 
sensitivity was improved and the detection strength. Even if the low molecules which have week 
fluorescent, it was confirmed that this speedy and in-situ 3D measurement is able to sufficiently 
detect to a low concentration of around 10 ppm and it is very powerful tool to discriminate the 
medical products in the injectable formulation. 
 
The developed analytical methods shown in Chapter I to III are expected to be applied widely as the 
powerful tools for detecting SFs in the research institutes, authorities and the pharmaceutical industry. 
This investigation succeeded to detect of SFs for the oral solid pharmaceutical products and the 
injectable solutions circulating in the Asian market using the pharmacopeial quality tests and 
non-destructive spectroscopy using the X-ray CT, the portable Raman, PCA, and the fluorescence 
spectrophotometer. The physical and chemical properties ant those correlation among the samples 
were clarified in this study. Through the chapter I to III, the discrimination methods of the 
substandard and falsified medical products for both the solid formulation and injectable formulation 
were developed using the pharmacopeial quality tests, non-destructive spectroscopy of Raman 
spectroscopy and X-ray CT, decision tree and PCA model. The application results of the developed 
methods to the SFs and the medical products showed that these methods have sufficient performance 
to detect the SFs with speedy and in-situ and to understand the physical and chemical properties and 
risks of the SFs which are distributing in the actual market. These methods are expected to contribute 
for detecting the SFs and to help people are able to access the reliable health care. 
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